Oral Microbial Shift Following 1-Month Supplementation of Probiotic Chewable Tablets Containing UBLRu-87 as an Adjunct to Phase 1 Periodontal Therapy in Chronic Periodontitis Patients: A Randomized Controlled Clinical Trial.

CONTEXT

Although as a probiotic was established as a treatment for a wide range of systemic infections, its role in periodontitis and oral microbiota is still under investigation.

AIMS

The present randomized clinical trial was aimed to evaluate the effects of probiotic chewable tablets containing along with initial periodontal therapy on clinical parameters and oral microbiota of chronic periodontitis (CP) patients.

SETTINGS AND DESIGN

The randomized controlled clinical trial.

SUBJECTS AND METHODS

Thirty CP patients were selected who received scaling and root planing (SRP) and were randomly allocated into two treatment groups; Groups A and B. Group A received -containing chewable probiotic tablets. The clinical parameters (plaque index, gingival index, probing pocket depth, clinical attachment level), and microbiological parameters ( and levels using real-time polymerase chain reaction) were evaluated at baseline, following treatment at 1 month and 3 months in both groups.

STATISTICAL ANALYSIS

Paired -test and unpaired -test were used for the statistical analysis.

RESULTS

On intergroup analysis, statistically significant improvement in clinical as well as microbiological parameters was observed in Group A (SRP + PROBIOTIC) compared to Group B (SRP ALONE) at all evaluation time points.

CONCLUSION

Probiotic chewable tablets containing may be a useful adjunct along with initial periodontal therapy to slow recolonization of periopathogens along with improvement in clinical outcomes of CP. Further long-term trials are necessary to establish the optimal dosage of probiotics.